Imutex's Universal Flu Vaccine Inches Forward On New Data
Executive Summary
The Imutex joint venture between hVIVO and the SEEK Group updates promise of its universal flu vaccine candidate after additional data from a Phase IIb study showed a statistically significant effect on its primary endpoint.